{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T06:49:51Z","timestamp":1790232591962,"version":"4.1.0"},"reference-count":42,"publisher":"Wiley","issue":"22","license":[{"start":{"date-parts":[[2009,8,11]],"date-time":"2009-08-11T00:00:00Z","timestamp":1249948800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2009,11,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND:<\/jats:title><jats:p>Currently, there are no consensus guidelines regarding the best therapeutic option for patients with extranodal marginal zone lymphomas of the mucosa\u2010associated lymphoid tissue (MALT) type.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS:<\/jats:title><jats:p>Patients with systemically untreated or de novo extranodal MALT lymphoma received rituximab 375 mg\/m<jats:sup>2<\/jats:sup> intravenously on Day 1 and fludarabine 25 mg\/m<jats:sup>2<\/jats:sup> intravenously on Days 1 through 5 (Days 1\u20103 in patients aged &gt;70 years) every 4 weeks, for 4 to 6 cycles. After the first cycle, oral fludarabine could be given orally at 40 mg\/m<jats:sup>2<\/jats:sup> on the same schedule. After 3 cycles, a workup was done. Patients who achieved a complete remission (CR) received an additional cycle, and patients who achieved a partial remission (PR) received a total of 6 cycles.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS:<\/jats:title><jats:p>Twenty\u2010two patients were studied, including 12 patients with gastric lymphoma and 10 patients with extragastric MALT lymphoma. Six patients (27%) had stage IV disease. In total, 101 cycles were administered (median, 4 cycles per patients). After the third cycle, 13 patients (62%) achieved a CR, and 8 patients (38%) achieved a PR. Primary extragastric disease was an adverse factor to achieve CR after 3 cycles of chemotherapy (hazard ratio, 23.3; 95% confidence interval, 2.0\u2010273.3). At the end of treatment, the overall response rate was 100%, and 90% of patients achieved a CR. The progression\u2010free survival rate at 2 years in patients with gastric and extragastric MALT lymphoma was 100% and 89%, respectively. Toxicities were mild and mainly were hematologic.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS:<\/jats:title><jats:p>Combination therapy with rituximab and fludarabine is a very active treatment with favorable safety profile as first\u2010line systemic treatment for patients with extranodal MALT lymphoma. Cancer 2009. \u00a9 2009 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.24605","type":"journal-article","created":{"date-parts":[[2009,8,11]],"date-time":"2009-08-11T15:54:48Z","timestamp":1250006088000},"page":"5210-5217","source":"Crossref","is-referenced-by-count":76,"title":["Combination therapy with rituximab and intravenous or oral fludarabine in the first\u2010line, systemic treatment of patients with extranodal marginal zone B\u2010cell lymphoma of the mucosa\u2010associated lymphoid tissue type"],"prefix":"10.1002","volume":"115","author":[{"given":"Antonio","family":"Salar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Domingo\u2010Domenech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Estany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel A.","family":"Canales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Gallardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Octavio","family":"Servitje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guadalupe","family":"Fraile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Montalb\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,11,3]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19831015)52:8<1410::AID-CNCR2820520813>3.0.CO;2-3"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.5.1361.1361"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1997.tb00982.x"},{"key":"e_1_2_6_5_2","first-page":"157","volume-title":"World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues","author":"Isaacson PG","year":"2001"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.4.1624"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1254"},{"key":"e_1_2_6_8_2","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1182\/blood.V95.3.802.003k19_802_806","article-title":"Mucosa\u2010associated lymphoid tissue lymphoma is a disseminated disease in 1 third of 158 patients analyzed","volume":"95","author":"Thieblemont C","year":"2000","journal-title":"Blood"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(93)91409-F"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)90113-2"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-122-10-199505150-00006"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a059184"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.1800800908"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.18.3874"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(01)01549-8"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-57054-4_14"},{"key":"e_1_2_6_17_2","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1182\/blood.V85.4.1075.bloodjournal8541075","article-title":"A clinical analysis of 2 indolent lymphoma entities: mantle cell lymphoma and marginal zone lymphoma (including the mucosa\u2010associated lymphoid tissue and monocytoid B\u2010cell subcategories): a Southwest Oncology Group study","volume":"85","author":"Fisher RI","year":"1995","journal-title":"Blood"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197603)37:3<1275::AID-CNCR2820370307>3.0.CO;2-M"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.10.2524"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.05.117"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008388824069"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdg492"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04586.x"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.08.128"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1159\/000074641"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-11-3496"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.1.268"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011795"},{"key":"e_1_2_6_29_2","first-page":"1005","article-title":"Fludarabine. An update of its pharmacology and use in the treatment of haematological malignancies","volume":"43","author":"Adkins JC","year":"1997","journal-title":"Drugs"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdj069"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.9313"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.5.1574"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.thj.6200113"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-1010385"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a058869"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.52.11.1656"},{"key":"e_1_2_6_38_2","unstructured":"Cancer Therapy Evaluation Program National Cancer Institute. Common Toxicity Criteria. NCI\u2010CTC version 3.0. Bethesda Md: National Cancer Institute 1998. Available at:http:\/\/ctep.cancer.gov\/reporting\/CTC\u20103.html. Accessed August 9 2006."},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.6138"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1159\/000079502"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-04-1258"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.8.2825"},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.2830490207"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.24605","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.24605","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T15:49:43Z","timestamp":1760284183000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.24605"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11,3]]},"references-count":42,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2009,11,15]]}},"alternative-id":["10.1002\/cncr.24605"],"URL":"https:\/\/doi.org\/10.1002\/cncr.24605","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,11,3]]}}}